Bioequivalence of a 2.5 mg Linagliptin / 850 mg Metformin Fixed Dose Combination Tablet Compared With Single Linagliptin 2.5 mg and Metformin 850 mg Tablets in Healthy Volunteers

Phase 1

Completed

• Conditions: Healthy
• Interventions: Drug: Linagliptin/Metformin FDC; Drug: Linagliptin; Drug: Metformin

• Registration Number: NCT02220647
• Lead Sponsor: Boehringer Ingelheim

Brief Summary

Study to assess bioequivalence of a 2.5 mg linagliptin / 850 mg metformin fixed dose combination (FDC) tablet compared to single tablets of linagliptin 2.5 mg and metformin 850 mg administered together

Detailed Description

Not available

Study Timeline

• Study Start: 2010-01
• Primary Completion: 2010-04
• Status Verified: 2014-08
• Study First Submitted: 2014-08-19
• Study First Submitted QC: 2014-08-19
• Last Update Submitted: 2014-08-19
• Study First Posted: 2014-08-20
• Last Update Posted: 2014-08-20

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 96

Inclusion Criteria

1. Healthy men and women according to the following criteria: based upon a complete medical history, including physical examination, vital signs (Blood pressure (BP), Pulse Rate (PR)), 12-lead ECG, clinical laboratory tests
2. Age 18 to 55 years (inclusive)
3. Body mass index (BMI) 18.5 to 29.9 kg/m2 (inclusive)
4. Signed and dated written informed consent prior to admission to the study in accordance with Good Clinical Practice (GCP) and the local legislation

Exclusion Criteria

1. Any finding of the medical examination (including BP, PR and ECG) deviating from normal and of clinical relevance

2. Any evidence of a clinically relevant concomitant disease

3. Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunological or hormonal disorders

4. Surgery of the gastrointestinal tract (except appendectomy)

5. Diseases of the central nervous system (such as epilepsy) or psychiatric disorders or neurological disorders

6. History of relevant orthostatic hypotension, fainting spells or blackouts

7. Chronic or relevant acute infections

8. History of relevant allergy or hypersensitivity (including allergy to drug or its excipients)

9. Intake of drugs within 1 month or less than 10 half-lives of the respective drug prior to first study drug administration

10. Participation in another trial with an investigational drug within 2 months prior to administration or during the trial

11. Smoker (more than 10 cigarettes or 3 cigars or 3 pipes daily)

12. Alcohol abuse (average consumption of more than 20 g/day in women and 30 g/day in men)

13. Drug abuse

14. Blood donation (more than 100 mL within 4 weeks before Day 1 of Visit 2)

15. Any laboratory value outside the reference range of clinical relevance

16. Inability to comply with dietary regimen of trial site

    For female subjects of childbearing potential only:

17. Positive pregnancy test, pregnancy or planning to become pregnant during the study or within 2 months after study completion

18. No adequate contraception during the study and until 1 month after study completion, e.g. not any of the following: implants, injectables, combined hormonal contraceptives, hormonal intrauterine device, sexual abstinence for at least 1 month prior to first study drug administration, vasectomised partner (vasectomy performed at least 1 year prior to enrolment), or surgical sterilization (including hysterectomy). Women who did not have a vasectomised partner, were not sexually abstinent or surgically sterile were asked to use an additional barrier method (e.g. condom).

19. Lactation

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: CROSSOVER

Arm && Interventions

Group	Intervention	Description
Treatment B (single agents)	Metformin	-
Treatment A (FDC)	Linagliptin/Metformin FDC	-
Treatment B (single agents)	Linagliptin	-

Primary Outcome Measures

Name	Time	Method
AUC0-72 (area under the concentration-time curve of linagliptin in plasma over the time interval from 0 to 72 h)	up to 72 hours
AUC0-∞ (area under the concentration-time curve of metformin in plasma over the time interval from 0 extrapolated to infinity)	up to 72 hours
Cmax (maximum measured concentration of the analyte in plasma)	up to 72 hours

Secondary Outcome Measures

Name	Time	Method
AUC0-tz (area under the concentration-time curve of the analyte in plasma over the time interval from 0 to the time of the last quantifiable data point)	up to 72 hours
tmax (time from dosing to the maximum concentration of the analyte in plasma)	up to 72 hours
λz (terminal elimination rate constant in plasma)	up to 72 hours
t1/2 (terminal half-life of the analyte in plasma)	up to 72 hours
MRTpo (mean residence time of the analyte in the body after peroral administration)	up to 72 hours
AUC0-∞ (area under the concentration-time curve of linagliptin in plasma over the time interval from 0 extrapolated to infinity)	up to 72 hours
%AUCtz-∞ (percentage of AUCtz-∞ obtained by extrapolation)	up to 72 hours
AUCt1-t2 (area under the concentration-time curve of the analyte in plasma over the time interval t1 to t2)	up to 72 hours
CL/F (apparent clearance of the analyte in the plasma after extravascular administration)	up to 72 hours
Vz/F (apparent volume of distribution during the terminal phase λz following an extravascular dose)	up to 72 hours
Assessment of tolerability by investigator on a 4-point scale	up to 7 days after drug administration
Number of subjects with clinically significant findings in vital signs	up to 7 days after drug administration	blood pressure, pulse rate
Number of subjects with clinically significant findings in 12-lead electrocardiogram (ECG)	up to 7 days after drug administration
Number of subjects with clinically significant findings in laboratory tests	up to 7 days after drug administration
Number of subjects with adverse events	up to 7 days after drug administration